13 Jan 2021

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Read More
9 Jan 2021

Disposals of own shares

Read More
18 Dec 2020

Disposals of own shares

Read More
4 Dec 2020

Disposals of own shares

Read More
20 Nov 2020

Disposals of own shares

Read More
17 Nov 2020

UCB’s VIMPAT[®] (lacosamide) CV now approved by FDA in U.S. for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Read More
12 Nov 2020

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Read More
10 Nov 2020

Disposals of own shares

Read More
6 Nov 2020

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Read More
31 Oct 2020

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira[®] in Moderate-to-Severe Psoriasis Patients

Read More
Subscribe to